text:
Tampa Car Accident Lawyers > Blog > Personal Injury > MILLIONS AWARDED TO VICTIM OF CANCER-CAUSING ROUNDUP WEED KILLER
MILLIONS AWARDED TO VICTIM OF CANCER-CAUSING ROUNDUP WEED KILLER
A San Francisco jury recently found the mega-company Monsanto liable for a school groundskeeper's lymphoma that he said developed after years of applying the company's trademarked Roundup weed killer.
The $289-million verdict in San Francisco County Superior Court is certain to add momentum to a multi-front battle to ban Roundup's main active ingredient, glyphosate. The compound is applied to millions of acres of crops, many of which have been genetically modified to withstand the herbicide.
Monsanto Company was an agrochemical and agricultural biotechnology corporation. It was headquartered in Creve Coeur, Greater St. Louis, Missouri. Monsanto developed Roundup, a glyphosate-based herbicide in the 1970s, and became a major producer of genetically engineered crops. In September 2016, Bayer announced its intent to acquire Monsanto for US$66 billion. After gaining US and EU regulatory approval, the sale was completed on June 7, 2018.
Monsanto's roles in agricultural changes, biotechnology products and lobbying of government agencies and roots as a chemical company resulted in controversies. The company once manufactured controversial products such as the insecticide DDT, PCBs, Agent Orange and recombinant bovine growth hormone. Its seed patenting model was criticized as biopiracy and a threat to biodiversity.
The jury deliberated three days before awarding $39 million in compensatory damages and $250 million in punitive damages to groundskeeper DeWayne Lee Johnson, 46. He claimed that years of applying Monsanto's Roundup and Ranger Pro to school properties in a Bay Area suburb of Benicia caused his incurable non-Hodgkin's lymphoma.
Activists, who have long battled to ban glyphosate, lauded the decision in the closely watched trial.
"Monsanto made Roundup the OxyContin of pesticides, and now the addiction and damage they caused have come home to roost," said Ken Cook, president of Environmental Working Group. "This won't cure DeWayne Lee Johnson's cancer, but it will send a strong message to a renegade company."
"The jury found Monsanto acted with malice and oppression because they knew what they were doing was wrong and doing it with reckless disregard for human life," said Robert F. Kennedy Jr., one of Johnson's attorneys, according to the Associated Press.
"This should send a strong message to the boardroom of Monsanto," Kennedy added.
The verdict "signals a turning tide," said Linda Wells, Midwest organizing director for Pesticide Action Network. "It's time to get carcinogenic pesticides off the market, and fight for the protective regulations we all deserve," Wells said.
Monsanto, which continues to be run independently after merging earlier this year with German agro-industrial giant Bayer AG, said in a statement that it will appeal the verdict.
"We are sympathetic to Mr. Johnson and his family," said Scott Partridge, Monsanto's vice president of global strategy. "Today's decision does not change the fact that more than 800 scientific studies and reviews — and conclusions by the U.S. Environmental Protection Agency, the U.S. National Institutes of Health and regulatory authorities around the world — support the fact that glyphosate does not cause cancer, and did not cause Mr. Johnson's cancer."
The bulk of glyphosate was sprayed on tens of millions of acres of corn and soy in the Midwest. But California growers also applied it to more than 200 crops across 4 million acres, including 1.5 million acres of almonds, making it their most widely used herbicide, according to the California Department of Pesticide Regulation.
Having inherited a company long vilified by environmental activists as "Monsatan," Bayer faces high potential liabilities from hundreds of similar lawsuits, along with a battle over adding a cancer warning label on products sold in California.
Johnson's is the first of hundreds of cancer-patient cases against Monsanto and could be a bellwether of what lies ahead for the company.
A U.S. District Court judge earlier this year temporarily halted moves by California to require a cancer warning label under Proposition 65, the Safe Drinking Water and Toxic Enforcement Act, passed by voters in 1986.
California's decision to include glyphosate on its list of chemicals linked to cancer followed a 2015 ruling by the Europe-based International Agency for Research on Cancer that the chemical is a "probable" carcinogen.
The U.S. EPA as well as its counterpart agencies in the European Union have disagreed with the conclusion reached by that panel, which is part of the World Health Organization. Last December, the U.S. EPA ruled that glyphosate was "not likely" to cause cancer.
Nationwide, growers have used an estimated 1.8 million tons of the chemical since it was introduced in the mid-1970s, according to government and industry estimates.
California's Office of Environmental Health Hazard Assessment, the agency that listed the chemical as a probable carcinogen, is finalizing its regulation establishing a "safe" threshold under which glyphosate products would be exempt from the Proposition 65 warning provisions.
Contact The Matassini Law Firm, P.A. for a free, confidential evaluation of your product safety claim. Since 1976, we have been assisting victims of harmful consumer products seek justice for their injuries and damages. Visit us www.matassinilaw.com .
« MEDICAL MALPRACTICE FREQUENTLY ASKED QUESTIONS
St. Petersburg Car Crash Kills Teen Mom And Her Baby »


text:
Q: In a time series, find the longest subsequent period for which a condition is met i need to search through dataframe, as follows:
if grade goes above 50% at time=1, then drops below 50% at time=3, then above at time=4 and below at time=7, then abpve at time 8 and below at time 12, etc.
... then it was above for 2 seconds, then 3 seconds, then 4 seconds, etc.
... so the final result required is max time above 50%, which is 4 seconds in this case (as per data frame section below).
so i need thje value of 4 to be assigned to max(maxGradeTimePeriod)
simple code for this please?  thanks in advance.
this is what i have tried thus far ( 1 of many attempts!):
    maxGradeTimePeriod <- c()
    i <- 1

    while (i <= nrow(df)) {
            if (0.5 <= df$Grade[i]) {
                    p <- i+1
                    k <- p
                    while (k < (nrow(df)-1)) {
                            if (df$Grade[k] < 0.5) {
                                    time <- (df$Time[k-1])-df$Time[i]
                                    print(time)
                                    maxGradeTimePeriod <- append(maxGradeTimePeriod, time)
                            }
                            else {
                                    time <- max(df$Time)-df$Time[i]
                                    maxGradeTimePeriod <- append(maxGradeTimePeriod, time)
                                                                            }
                            k <- k+1
                            }
                    }
                    i <- i+1
            }
            else {
                    i <- i+1
            }
    }

sample data frame:
 time grade
    1   0.5
    2   0.5
    3   0.1
    4   0.5
    5   0.5
    6   0.5
    7   0.1
    8   0.5
    9   0.5
   10   0.5
   11   0.5
   12   0.1
   13   0.5
   14   0.5
   15   0.5
   16   0.1
   17   0.5
   18   0.5
   19   0.1
   20   0.5

A: Assuming that each row is one time unit, try:
y <- rle(x$grade >= 0.5)              # Find clusters of values not below 0.5
max(y$length[which(y$values)])        # Find which TRUE cluster is the largest
# [1] 4

It could be that the time points do not have even spacing. In that case, try:
x2 <- rle(x$grade >= 0.5)$length      # Get all clusters
x3 <- rep(seq_along(x2), x2)          # Make a vector that specifies cluster per value
time <- c(0, diff(x$time))            # Make a new vector with time differences
y <- aggregate(time ~ x3, FUN=sum)    # Aggregate the sum of time per cluster
max(y$time)                           # Take the max
# [1] 4

redpajama_set_name: RedPajamaStackExchange


There's a new option out there for buyers seeking a four-seater Ferrari. Those who don't need all the falderal of the GTC4Lusso's 12 cylinders can opt for a version with a twin-turbo turbo V-8. Ferrari calls the GTC4Lusso T "sporty and versatile, as well as perfect for driving on a daily basis."
The car is the first four-seater Ferrari to receive a turbocharged V-8. The 3.9-liter unit pumps out 600 hp, down from the standard model's 680 ponies. But it offers a whopping 560 lb-ft of torque, an increase from 514 lb-ft in the V-12 model. Ferrari estimates the T can hit 62 mph in just 3.5 seconds, or 0.1 second slower than the V-12. The GTC4Lusso is the latest model to receive a version of Ferrari's new boosted eight-cylinder, following the 488 GTB and California T. Compared to the 3.9-liter in the 488, the GTC4Lusso's is down 60 hp, though it's up 48 hp from the unit in the California T.
Unlike its V-12 sibling, the Ferrari GTC4Lusso T is a rear-wheel-drive car. Ferrari says it's also lighter and increases weight bias toward the rear. For sharper cornering maneuvers, the car offers Side Slip Control and four-wheel steering to steer the rear wheels in the same direction as the fronts.
Debuting at the Geneva Motor Show earlier this year, the GTC4Lusso replaces the shooting brake FF. Inside, it features an upgraded interior complete with a central 10.25-inch touchscreen and a dual cockpit setup that gives the passenger side its own screen. These tech tidbits also carry over to the T model.
The Ferrari GTC4Lusso T will make its official debut at the Paris Motor Show next week.


Following his inaugural season with Gill St. Bernard's, in which he guided the varsity girls' tennis team to a 14-2 record (12-1 conference), head tennis coach Patrick Hensley was named Skyland Conference Coach of the Year. He began working with the team in mid-August, along with coach Chris Walsh, focusing on fundamental strategies for long-term success.
Hensley holds certification as a tennis instructor from the United States Professional Tennis Association and has played competitively at Division II Francis Marion University and tournament levels. In addition to working with the varsity program, Hensley coaches the Middle School tennis teams at Gill and he is also a tennis coach at the Chester Tennis Club.


Within the framework of the promotion of Social Business aiming the self government of Socially Vulnerable Persons and their fully participation in the development of Cameroon, the Minister of Social Affairs, Mrs Pauline Irene NGUENE presided over the official launching ceremony of the activities of the Support Programme for the vocational integration and reintegration of Vulnerable Persons (PAIRPPEV) on thursday, April 7, 2016 at the headquarters of the said programme at the Total Fouda Round about in Yaounde.
On this occasion, thirty former street children received support for the implementation of income-generating micro-projects.
The PAIRPEV is implemented as part of a partnership agreement between the Ministry of Social Affairs and the National Employment Fund. It provides opportunities of direct integration, training, promotion of self-employment projects to Socially Vulnerable Persons through support in project setting up, monitoring and supervision.


text:
Clinical Investigation of a Humanized Anti-CD47 Antibody in Targeting Cancer Stem Cells in Hematologic Malignancies and Solid Tumors
Disease Team Therapy Development III
DR3-06965
Clinical Investigation of a Humanized Anti-CD47 Antibody in Targeting Cancer Stem Cells in Hematologic Malignancies and Solid Tumors.
The project objective is to complete two staggered Phase 1 clinical trials, beginning with a solid tumor trial at Stanford. The second trial in AML will be conducted at Oxford in the UK and at Stanford and will be jointly funded by MRC and CIRM.
Irving Weissman
Ravindra Majeti
Co-PI
Partner-PI
Disease Focus:
Collaborative Funder:
Human Stem Cell Use:
Cancer Stem Cell
We have previously developed a new therapeutic candidate, the anti-CD47 humanized antibody, Hu5F9-G4, which demonstrates potent anti-cancer activity in animal models of malignancy. The goal of CIRM DTIII Grant DR3-06965 is to conduct initial phase I clinical trials of this antibody in advanced cancer patients. We originally proposed to conduct two separate Phase I clinical trials: one in solid tumor patients with advanced malignancy (commenced in August 2014), the other in relapsed, refractory AML patients (anticipated to start in September 2015). The primary endpoints for these trials will be to assess safety and tolerability, and additional endpoints include obtaining information about the dosing regimen for subsequent clinical investigations, and initial efficacy assessments. CD47 is a dominant anti-phagocytosis signal that is expressed on all types of human cancers assessed thus far. It binds to SIRPα, an inhibitory receptor on macrophages, and in so doing, blocks the ability of macrophages to engulf and eliminate cancer cells. Hu5F9-G4 blocks binding of CD47 to SIRPα, and restores the ability of macrophages to engulf or phagocytose cancer cells. In pre-clinical cancer models, treatment with Hu5F9-G4 shrunk tumors, eliminated metastases, and in some cases resulted in long-term protection from cancer recurrence. These results suggest that Hu5F9-G4 leads to elimination of cancer stem cells in addition to differentiated cancer cells. We have developed Hu5F9-G4 for human clinical trials by demonstrating safety and tolerability in pre-clinical toxicology studies. These studies also indicated that we can achieve serum levels associated with potent efficacy in pre-clinical models. The regulatory agencies (FDA in the U.S., and MHRA in the U.K.) reviewed the large package of pre-clinical data describing Hu5F9-G4, and approved our requests to commence separate Phase I clinical trials in solid tumor and AML patients. The solid tumor trial commenced at Stanford in August 2014 and has been designed to assess patients in separate groups, or cohorts, treated with increasing doses of Hu5F9-G4. The trial is ongoing as primary endpoints have not been met. The acute myeloid leukemia trial has been given regulatory approval in the U.K., and will start enrolling patients in September 2015. In summary, during the last year, the Hu5F9-G4 clinical trials have made substantial progress and all milestones have been met.
With the support of CIRM DT (DR1-01485) we developed Hu5F9-G4, a humanized monoclonal CD47-blocking antibody as a novel immunotherapy for patients with hematological malignancies and solid tumors. CD47 is an anti-phagocytic "don't eat me" signal that is expressed at relatively high levels on most human cancers. Inhibition of CD47-SIRPalpha signaling enables anti-tumor targeting through the innate and adaptive immune system in a broad range of preclinical in vivo models. The goal of CIRM DTIII Grant (DR3-06965) is to conduct phase I clinical trials to determine safety and establish the dose for subsequent trials that will explore the efficacy of the novel antibody. Hu5F9-G4 is currently being explored in two phase 1 trials; one for patients with solid tumors at Stanford University that started in August 2014 (NCT02216409) and a multi-center study for patients with acute myelogenous leukemia (AML) in the United Kingdom (NCT02678338) that started in December 2015. The primary objectives for both trials are to assess safety and tolerability, secondary objectives are to assess pharmaco-kinetics (PK) and pharmaco–dynamics (PD). The solid tumor trial consists of two parts, Part A to determine the optimal first "Priming" dose, and Part B to determine the optimal "Maintenance" dose. The priming dose has been identified and the trial has progressed from Part A to part B to determine to the optimal maintenance dose. No dose limiting toxicities have occurred in Part B and the study continues dosing as planned an according to the milestones. The AML trial has administered Hu5F9-G4 to the patients in the first two dosing cohorts. The infusions have been well tolerated and the trial is progressing according to the study design and the milestones of the grant. In summary, during the last year, the Hu5F9-G4 clinical trials have made substantial progress and milestones have been met.
Most normal tissues are maintained by a small number of stem cells that can both self-renew to maintain stem cell numbers, and also give rise to progenitors that make mature cells. We have shown that normal stem cells can accumulate mutations that cause progenitors to self-renew out of control, forming cancer stem cells (CSC). CSC make tumors composed of cancer cells, which are more sensitive to cancer drugs and radiation than the CSC. As a result, some CSC survive therapy, and grow and spread. We sought to find therapies that include all CSC as targets. We found that all cancers and their CSC protect themselves by expressing a 'don't eat me' signal, called CD47, that prevents the innate immune system macrophages from eating and killing them. We have developed a novel therapy (anti-CD47 blocking antibody) that enables macrophages to eliminate both the CSC and the tumors they produce. This anti-CD47 antibody eliminates human cancer stem cells when patient cancers are grown in mice. At the time of funding of this proposal, we will have fulfilled FDA requirements to take this antibody into clinical trials, showing in animal models that the antibody is safe and well-tolerated, and that we can manufacture it to FDA specifications for administration to humans.
Here, we propose the initial clinical investigation of the anti-CD47 antibody with parallel first-in-human Phase 1 clinical trials in patients with either Acute Myelogenous Leukemia (AML) or separately a diversity of solid tumors, who are no longer candidates for conventional therapies or for whom there are no further standard therapies. The primary objectives of our Phase I clinical trials are to assess the safety and tolerability of anti-CD47 antibody. The trials are designed to determine the maximum tolerated dose and optimal dosing regimen of anti-CD47 antibody given to up to 42 patients with AML and up to 70 patients with solid tumors. While patients will be clinically evaluated for halting of disease progression, such clinical responses are rare in Phase I trials due to the advanced illness and small numbers of patients, and because it is not known how to optimally administer the antibody. Subsequent progression to Phase II clinical trials will involve administration of an optimal dosing regimen to larger numbers of patients. These Phase II trials will be critical for evaluating the ability of anti-CD47 antibody to either delay disease progression or cause clinical responses, including complete remission. In addition to its use as a stand-alone therapy, anti-CD47 antibody has shown promise in preclinical cancer models in combination with approved anti-cancer therapeutics to dramatically eradicate disease. Thus, our future clinical plans include testing anti-CD47 antibody in Phase IB studies with currently approved cancer therapeutics that produce partial responses. Ultimately, we hope anti-CD47 antibody therapy will provide durable clinical responses in the absence of significant toxicity.
Cancer is a leading cause of death in the US accounting for approximately 30% of all mortalities. For the most part, the relative distribution of cancer types in California resembles that of the entire country. Current treatments for cancer include surgery, chemotherapy, radiation therapy, biological therapy, hormone therapy, or a combination of these interventions ("multimodal therapy"). These treatments target rapidly dividing cells, carcinogenic mutations, and/or tumor-specific proteins. A recent NIH report indicated that among adults, the combined 5-year relative survival rate for all cancers is approximately 68%. While this represents an improvement over the last decade or two, cancer causes significant morbidity and mortality to the general population as a whole.
New insights into the biology of cancer have provided a potential explanation for the challenge of treating cancer. An increasing number of scientific studies suggest that cancer is initiated and maintained by a small number of cancer stem cells that are relatively resistant to current treatment approaches. Cancer stem cells have the unique properties of continuous propagation, and the ability to give rise to all cell types found in that particular cancer. Such cells are proposed to persist in tumors as a distinct population, and because of their increased ability to survive existing anti-cancer therapies, they regenerate the tumor and cause relapse and metastasis. Cancer stem cells and their progeny produce a cell surface 'invisibility cloak' called CD47, a 'don't eat me signal' for cells of the native immune system to counterbalance 'eat me' signals which appear during cancer development. Our anti-CD47 antibody counters the 'cloak', enabling the patient's natural immune system to eliminate the cancer stem cells and cancer cells. Our preclinical data provide compelling support that anti-CD47 antibody might be a treatment strategy for many different cancer types, including breast, bladder, colon, ovarian, glioblastoma, leiomyosarcoma, squamous cell carcinoma, multiple myeloma, lymphoma, and acute myelogenous leukemia.
Development of specific therapies that target all cancer stem cells is necessary to achieve improved outcomes, especially for sufferers of metastatic disease. We hope our clinical trials proposed in this grant will indicate that anti-CD47 antibody is a safe and highly effective anti-ancer therapy that offers patients in California and throughout the world the possibility of increased survival and even complete cure.
Source URL: https://www.cirm.ca.gov/our-progress/awards/clinical-investigation-humanized-anti-cd47-antibody-targeting-cancer-stem-cells

redpajama_set_name: RedPajamaCommonCrawl


JetBlue is bringing its Mint premium cabin product to Boston in early 2016, ending months (if not years) of speculation on the topic. The Mint service will launch between Boston and San Francisco in March 2016 with up to three daily round trip flights. Seasonal Saturday-only service to Barbados will be added at the same time, taking advantage of reduced transcon flying on the weekend, similar to the winter Caribbean Mint service launching from JFK this November. Los Angeles service will be added in the Fall of 2016 as additional Mint aircraft are delivered.
These two markets out of Boston represent separate competitive scenarios. For San Francisco both United Airlines (8x) and Virgin America (4x) serve the route, each with more frequencies than JetBlue (3x). JetBlue will be the only to offer a regularly scheduled, truly premium cabin service on the route, however. It could be argued that the Virgin America product was such when it initially launched and United has intermittent premium flights this summer, but neither is consistent nor to the level which JetBlue is offering.
For Los Angeles the competition is even more stiff, with American Airlines (4x) and Delta Air Lines (2x) also plying the route, along with Virgin America (3x) and United (2x) to go with JetBlue's thrice-daily service. While there are more frequencies overall to San Francisco there is broader competition to Los Angeles with fares to the Bay area generally higher up front than fares to the south. In both cases, however, the typical one-way premium cabin fare is above JetBlue's $599 Mint intro price, though the company has not confirmed that will be the price from Boston; it is currently the low water mark in the JFK markets.
Today's news comes on the heels of the carrier announcing last week increases in Mint frequencies to/from JFK as United Airlines pulled out of that market, shifting its premium transcon capacity to Newark. At that time the company suggested travelers "stay tuned" for this sort of news. It did not take long to get the details ironed out and secure the conversion of the pending A321 aircraft deliveries to the Mint configuration to allow the increase of service. Of course, converting these deliveries to Mint means fewer total seats flying as they come online which may affect the overall ASM growth for the company. And keeping that a bit lower should please analysts who like to see less capacity and higher fares.
The (multi-)million dollar question with this move is whether there is truly a premium product demand for Boston, one which can support the higher fares necessary to sustain the operation. Historically the truly premium domestic service has been reserved for the New York City market. And even some experiments there, such as Delta's efforts to expand premium offerings to Seattle, have fallen short of expectations. JetBlue does have a cost advantage versus the legacy carriers but with fewer frequencies than the legacies to both destinations that may not be enough to attract the business travelers who often seek schedule flexibility just as much as they seek comfort.
Also as part of the announcement, JetBlue will add Nashville to its route map with service from both Boston and Ft. Lauderdale. Further frequencies from Boston will also be added, with a peak summer 2016 schedule set near 140 daily departures.


Atlanta real estate blog featuring the best neighborhoods in Atlanta, Atlanta schools, news and events.
Fernbank After Dark offers exclusive Museum access after dark with a variety of hands-on activities for adults! Don't miss live music, giant screen movies, craft beer and cocktails, and more at May's Art & Science!


Apple has today added a number of new Flyover locations to its Maps app for Mac and iOS. Places in Hawaii, Japan and Germany are among those just given the Flyover treatment.
Flyover has been a key feature of Maps since the app was launched with iOS 6 three years ago, and allows users to see various select areas around the globe recreated in 3D graphics. MacRumors has posted a complete list of the Flyover locations added today.
Apple Maps has developed into a very credible alternative to the longer-established Google Maps. We decided to pay a virtual visit to Bielefeld, and you can see the freshly-added Flyover version of the German city in our screenshot. Hawaii's Big Island, Switzerland's Basel and the Czech Republic's capital city Prague are also in the list of new Flyover inclusions.


From rough wood, to ceramic tile, plastics and metal cutting hole saws, AFT has the hole saws and hole cutters you need for your application. Ranging from under an inch to 6-1/4" you're certain to find the diameter hole saw bit you need. Shop our huge selection of carbide tipped, carbide grit, and bi-metal hole saws, or contact us today for a custom quote.
1" Bi-Metal Speed Slot Hole Saw Contractor's 5-Pk.
1-1/2" Bi-Metal Speed Slot Hole Saw Contractor's 5-Pk.
1-1/4" Bi-Metal Speed Slot Hole Saw Contractor's 5-Pk.
1-1/8" Bi-Metal Speed Slot Hole Saw Contractor's 5-Pk.


Mass Upload is a revolutionary way to create multiple payments in seconds. If your company has a need to pay or be paid for multiple invoices, your account manager can show you how Veem's platform can serve you. All your invoices in one fell swoop!


If you want a PCOS friendly diet, it's actually a good idea to have most of your calories at breakfast and then have a light lunch and dinner with a few snacks in between meals. A study from the American Friends of Tel Aviv University found that eating a calorie dense breakfast and lower calorie meals throughout the day resulted in lower levels of testosterone and a dramatic increase in ovulation frequency. For some breakfast ideas that work for PCOS click here.
So if you've had a calorie dense breakfast, what do you do to keep lunch light and nutritious? The following suggestions are go-to lunch ideas for many tastes and situations.
Trying to have a light, nutritious lunch with PCOS is a matter of achieving the right balance of protein, carbohydrates, and fats. If you make sure that there is a bit of all three in your lunch, you're going to ensure that your lunch is well balanced. For example, having a whole wheat pita with hummus and a tossed salad includes all the elements you need in your lunch and is delicious to boot.
You don't need too much protein, as women only need 1-2 servings of protein per day, but there should be some in your lunch as it will help fill you up and prevent excessive snacking later on in the day. When people think of protein, there is a tendency to go straight for the meat. While having something like chicken or salmon are excellent choices for your protein option, consider exploring plant-based options for protein.
Filling up on plant-based protein helps you avoid hormones that can be within meat and avoid mercury content in foods like tuna. Something like lentils, hemp seeds, or chia seeds are high in protein but help you avoid some of the undesirable qualities of meat. Women with PCOS do not have to completely switch over to plant-based protein, but including some throughout your week will add variety to your diet.
Carbohydrates should be chosen carefully. If you're including bread in your meal, make sure you're selecting a whole wheat option to prevent excessive spikes in blood sugar after lunch. Whole wheat bread or a whole wheat pita are good low GI choices that can be combined with something like tuna or salmon, with some lettuce and tomato on top. Add in a small amount of low fat mayonnaise for some extra flavor and you have a decent lunch right there.
You can also add carbohydrates in the form of a snack in your lunch, such as with whole-wheat pretzels or air-popped popcorn without butter or salt.
Fats are an important component of lunch, although you should avoid fats that contain hydrogenated or partially hydrogenated oils. Try adding in some nuts or trail mix as part of your lunch to get some healthy fats. Peanut butter is a good non-meat option that gets you both fat and protein, for example making a peanut butter and banana sandwich. If you're a fan of seeds, sunflower seeds or pumpkin seeds are a tasty way to get some fat into your lunch.
Some women with PCOS try to stay away from fruit because they're worried that fruit will cause blood sugar spikes. While fruit is high in sugar and could affect blood sugar levels, it really depends what fruit you're adding to your lunch. Something like dried dates or raisins rank higher on the GI and should be avoided as they are too sugary. Grapefruit, pear, or watermelon are some examples of fruits that would be okay and won't negatively affect your blood sugar levels.
If you're looking for a warm, filling lunch option, go with soups. Soups can be especially good for a chilly autumn or winter day. Another reason why soups are a good lunch choice for PCOS is soups are readily available: if you don't want to make homemade soup, there are plenty of options at the supermarket and they are also at most restaurants and fast-food places, making it a safer choice when you're going out for lunch.
Some low GI soup options include lentil, vegetable, chicken, and pea soup. It's best to avoid cream based soups though due to their high amount of calories and saturated fat. When having soup, you can include a whole wheat or pumpernickel roll to add some acceptable, low GI carbs to the meal.
If you don't like the idea of drinking your lunch in a soup or smoothie, you could try making a salad instead. There is plenty of variety when it comes to salads and there are many choices of vegetables that can be combined to make delicious salads.
Start with a nutrient dense lettuce like spinach or spring mix rather than iceberg lettuce. While iceberg lettuce isn't high on the glycemic index, it also doesn't have a lot of nutrients. By selecting something like spinach or spring mix instead, you can get some important nutrients like iron into your lunch. Some other vegetables that would be good to add to a low GI salad are tomatoes, cucumbers, peppers, mushrooms, broccoli, and carrots. You can also add a protein option such as hard boiled eggs, grilled chicken, salmon, or nuts. If you'd like some sweetness in your salad, put in some fruit like berries or apples.
The tricky thing about salads is it seems like they're low in calories, but that really depends on what type and how much dressing you put on the salad. Keep it simple with your salad dressing such as by putting a mixture of olive oil and balsamic vinegar on top.
And of course, it's always a smart idea to make use of your dinner leftovers instead of letting them go to waste in your fridge. Anything that you've had for dinner can be warmed up and used at lunch. Consider prepping some food beforehand like grilled chicken breasts or hard boiled eggs that can be paired with a dinner leftover like some leftover brown rice, or be used as part of a salad or sandwich.
As mentioned above, there are many combinations you can do to have creative, nutritious lunches. The most important thing is making sure you have a combination of protein, carbohydrates, and healthy fats to give you a well-rounded meal. How you actually include those elements can take many forms. You may want to have a minestrone soup with some yogurt and fruit on the side or maybe a leafy green salad with grilled chicken and a multigrain roll.
Remember that with a healthy diet for PCOS, it's essential you have a filling breakfast and lunch is simply meant to be light and prevent your blood sugars from dipping too low. What are some winning lunch combinations that work for you? Be sure to share in a comment!
Galan, Nicole. (4 February 2017) "Lunch Ideas for a Woman on a Low GI Diet." Retrieved from https://www.verywell.com/lunch-ideas-for-a-woman-on-a-low-glycemic-index-diet-2616574.
Hurley, Vanessa. (5 October 2005) "The GI Diet Made Easy." Retrieved from http://www.canadianliving.com/health/nutrition/article/the-gi-diet-made-easy.
Nall, Rachel. (28 January 2015) "Low GI School Lunch Ideas." Retrieved from http://www.livestrong.com/article/444244-low-gi-school-lunch-ideas/.
Will Genital Herpes Prevent You From Having Children?


text:
None of the children whose faces you see have been trafficked or in our care.
Sponsor a Staff Member
Action and Awareness Teams
she-cross
No.1 Education
No.2 Vocational
No.3 Therapeutic
No.4 Family Support
No.5 Medical
We are changing lives, one at a time.
No. 1 Education
All girls, regardless of their age, are given the gift education. From the time they are young children, girls in Cambodia are discriminated against and lag behind boys in education at every level. In poor families, girls are the first to be pulled out of school as they are needed at home to look after younger children or to help out in a family business. When it is safe to do so, the girls are enrolled in a private school, where they attend half-days, 6 days a week. They also receive further schooling in Computers and English classes by one of our staff, who is a teacher, each afternoon. For the girls whom it is not safe to enroll in school, they receive full day education with our teacher.
Our goal is that every girl would reach a minimum of a Year 6 level, where they can read and write Khmer competently. For many of our older girls, around the age of 15, have never been to school, or have only completed six months of Year 1 before coming to us, this can be a challenging discipline for them to learn to study and apply themselves. We consider it to be so important, for even the girls entering vocational training, to continue their education in being able to read and write.
No. 2 Vocational Training
We love that, in Cambodia, we're able to connect with many other great NGO's (non-government organizations) offering vocational training programs.
Some of our younger girls have expressed an interest in learning to sew as a means to earning an income to assist their families. We're able to send them to our Sewing Centre to learn these skills. As a result, they're able to make SHE items including fabric bags and hearts we sell internationally in both Australia and the USA. They love being able to earn money they can save towards goals they have personally set while many girls choose to also use some of their income to help their families by purchasing rice, vegetables, fruit or cooking utensils they're able to be present to their families and Family Visits. Not only is this significant to her family, but also gives her a great sense of self-worth and self-esteem… offering something to her family.
No. 3 Therapeutic Services
Each girl within the SHE Rescue Home has regular contact with a counselor and social worker. These are essential relationships in their healing and restoration journey. All girls in the home receive a minimum of weekly counselling when they first arrive, and this may be reduced to three-weekly during their time in our care. Counselling services continue even once a girl is safely reintegrated back to her family.
Our counselors provide specific trauma therapy for every girl, along with being a person who the girl can share about their day, their relationships, their family, and their fears. Counselors are often asked by the girls to pray with them or to simply sit and be there for them. We regularly send our counselors along to extra training and professional development to continue equipping them as such important people in our girls lives.
No. 4 Family Support
Our social workers work closely with families to help equip them to be able to receive their daughter back into their care. This process involes life skills training, employment assistance, vocational training, and sometimes involvement within our Family Assistance Program. Family needs are assessed regularly and we're often able to connect with other organisations who can also assist in supporting families particular needs. We were recently able to assist another mother receive treatment for a health condition poverty had not allowed her to treat for 13 years! Family support has also involved us building and repairing houses, gifting pigs and chickens to families, building animal shelters, helping communities access clean water, and educating communities. The aim of our work is to always be able to reintergrate a girl back into a safe, supportive, and stable family and community.
No. 5 Medical
All girls in our SHE Home receive regular medical care, including vaccinations, dental, optical, and any other necessary care. Due to their trauma, a number of the girls who enter our home need treatment for STIs and STDs. One of our girls also receives treatment and support for HIV. In 2011, a life-saving operation was given to one of our girls who had a heart condition of which she wasn't receiving enough oxygen to her heart. The condition was crippling and prevented her from engaging in the everyday life of a 12 year old. Thanks to the generous support of our sponsors, we were able to fly her to Singapore to receive the major heart surgery. She is now a bright, happy, growing and energetic young girl who proudly shows off her scar to all she meets.
Safety and security don't just happen, they are the result of collective consensus and public investment. We owe our children, the most vulnerable citizens in our society, a life free of violence and fear.
Girls in care
We are a safe-haven for survivors of or those at risk of rape, prostitution, and human trafficking.
Would you like to receive updates?
SHE Rescue home uses cookies to make this website better. You can read about how we use them in our privacy policy and you can change your cookie settings at any time.
Australian Office
Citipointe Church
322 Wecker Rd Brisbane
QLD 4152, Australia
+61 73343 8888 Email Us
USA MAILING OFFICE
Its Not OK
2572 Midpoint Dr
Fort Collins CO 80525
Global Development Group
Study Social Justice
Reintegrated Girls
Closing a Case
Micro Assistance
Sewing Centre
Action & Awareness Teams
eStall & Market Stall
SHE Wellness Program
Shop AUS & NZ
Shop USA & INT
Website design by twoconleys.com Website development by webignite.com.au


text:
ADARA 2020
More Customers, Less Friction, Better Outcomes
The Global Leader in Permissioned Data and Verified Identity
Beyond the Segment – Data-informed Optimization to Enhance Your Digital Strategy – Amobee
Mission Possible Series: Cracking The Code Of Customer Data … Learn More about Beyond the Segment – Data-informed Optimization to Enhance Your Digital Strategy – Amobee
New Account Origination
Consortiumshttps://adara.com/wp-content/uploads/2020/09/product-consortiums-drm.svg
ADARA Privacy Tokenhttps://adara.com/wp-content/uploads/2020/10/product-privacy-token-1.svg
Digital Recognition Frameworkhttps://adara.com/wp-content/uploads/2020/09/product-digital-recognition-framework.svg
Impacthttps://adara.com/wp-content/uploads/2020/10/product-impact.svg
Cortexhttps://adara.com/wp-content/uploads/2020/09/product-cortex-catalog.svg
Cortex Catalog
Cortex Search
Customer Intelligence Center
Privacy & Guidelines
Brits are most resilient in Europe for travel bookings, finds new ADARA booking data
In a study of winter holiday bookings, ADARA finds Brits keen to travel abroad despite lockdown uncertainty
The announcement of the second lockdown led to UK travel departures soaring to four times previous levels
Bookings are last minute or very far in advance, with lots of uncertainty over the midterm
81% of UK bookings are for trips abroad
6% of EMEA consumer trips abroad are to the UK
AstraZeneca's effective vaccine announcement prompted a one-day 28% increase for international travel bookings from the UK
London, 9th December 2020: Adara, the leader in verified identity and permissioned data, reveals that the UK leads Europe in willingness to travel internationally. In a study of bookings, departures and searches from 10th November 2020 extending until early 2021, the data also shows that across Europe, travelers are either booking at the very last minute or far in advance as Covid-19 continues to create uncertainty.
This study reveals key insights into UK travelers' booking and searching behaviours. The second lockdown announcement had a huge impact, as the UK took advantage of the period pre-lockdown to get where they wanted to be. From when the lockdown was announced on 31st October until it commenced on 5th November, Brits departed on trips at four times the level prior to the 31st, driven by a 50% increase in bookings during those few days as people rushed to get home or to family members.
Adara also identified booking spikes after announcements around efficacy of Covid-19 vaccines, with Brits showing a one-day booking surge of 19% after the Pfizer announcement, 10% related to Moderna's and 28% after AstraZeneca's. The latter also led to a 154% week-on-week increase in searches for international holidays from hopeful Brits.
In fact, the UK is still raring to go abroad, with Brits making up 23% of all international bookings from EMEA, while France comes in second at almost half that level – 12%. Germany and Portugal each account for 8%, Spain 6% and Italy 5%. The UK is also booking vastly more international holidays than domestic – i.e. within the UK – with 81% of breaks by UK travelers international and just 19% domestic. Compare this to France, whose holiday goers are choosing staycations: over half (53%) are booking domestic (within France) trips rather than international. On the flipside, just 9% of travelers in both Switzerland and the Netherlands are booking domestically while 91% book internationally – showing that in these countries, the appetite for abroad is still very healthy.
In terms of destinations, bookings to the US from the EMEA area have fallen from 9% to 5% of outbound trips, as increasing infections combined with recent political uncertainty discourage travelers. France receives 12% of EMEA bookings, Spain 8%, Portugal and Saudi Arabia 6%, while the UK receives 6%. Central European countries receive about 18% of bookings within the top 10 destinations – up from 17% in 2019. It is interesting to note that within the EU, 56% of bookings from the UK are to non-travel corridor countries with high Covid infection rates.
However, Covid uncertainty is still having a huge impact on booking behaviors. Customers are either
booking and departing almost immediately or are looking at dates in the future when they perhaps believe there will be normality around travel. Booking-travel windows remain much shorter than in previous years with the 0-14 day window taking 30% share of the bookings for winter. On the other extreme, bookings over 90 days in advance are also accounting for 30% of bookings as people hope that vaccines or effective lockdowns mean they can plan for later down the line. Pre-Covid (1 Jan – 15 Mar) the last-minute booking window accounted for just 18% of bookings. As we approach Christmas and rules are relaxed for the festive period, we can expect to see a last-minute spike in booking activity as people travel home.
Carolyn Corda, CMO of ADARA, said: "What was historically a period dominated by short-haul trips to European cities or long haul trips to escape to the sun has changed to become short breaks planned quickly. Consumers have adapted the way they purchase travel to reflect ongoing uncertainties. However, the appetite for booking holidays is still there. We know that the desire to explore is a fundamental human drive, and that travel is set for a big bounceback as vaccines roll out and people feel more comfortable.
"For the travel industry, it's clear that in the meantime there is still an opportunity – as long as brands can convey their ability to deliver on a safe and responsible experience for customers. We are at the beginning of the end of the pandemic restrictions, but while we wait for the impact of global vaccine programmes, travel-loving Brits will find ways to scratch their holiday itch – if they can do so safely and securely."
Gill Browne / Ben Tozer: adara@propellergroup.com
ADARA's Field Data Science Team have used data from their consortium of travel partners, analyzing data for travel planned from November 2020 – February 2021, to view the rate of change for bookings and searches occurring during Winter 2020-21. These findings have been indexed for the purpose of comparison of different periods between the dates mentioned, allowing ADARA to find similarities, differences and observe catalyst points for sharp changes. The behavioral habits and demographics of the profiles booking and searching have also been analyzed, to highlight the changing practices of consumers in a year like no other.
About Adara
Adara, the global leader in permissioned data and verified identity, combines the power of global data consortiums to inform its 1.3 billion digital identities with over 22 billion data elements across 130 countries and serving Global 2,000 customers. Whether informing digital marketing, programmatic advertising, search, identity and verification, or stopping fraud, Adara provides you with more customers, less friction and better outcomes.
Consortiums
ADARA Privacy Token
Digital Recognition Framework
© 2020 ADARA Inc. All right reserved.
Japanese/English


text:
Saint-Barnabé è un comune francese di  abitanti situato nel dipartimento delle Côtes-d'Armor nella regione della Bretagna.

Società

Evoluzione demografica

Note

Altri progetti

Saint-Barnabe

redpajama_set_name: RedPajamaWikipedia